Clinical Trial Search

Primary: Change From Baseline up to 12 Hours Postdose in QT Interval Corrected for Heart Rate (QTc) — -7.1; -6.66; -7.7; -4.7 milliseconds

Primary: Patient Perceptions of Their Acne Treatment — 8; 8; 7; 7 score on a scale — p=0.677

Primary: Progression Free Survival — 70 percentage of no progression

Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0 Participants

Primary: Overall Survival — 55; 58 Participants

Primary: Number of Participants With Biochemically Verified Smoking Abstinence at Week 12 — 23; 34 Participants

Primary: Percentage of Participants With an Emergency Department (ED) Visit Within 6 Months After Enrollment — 41.60; 39.40 percentage of participants

Primary: Evaluate Change in Skin Appearance — 80.7 percentage of participants

Primary: Change in Masticatory Performance — 24; 13; 25; 16 percentage of masticated peanuts

Primary: Pelvic Floor Muscle Function Measured by Digital Palpation — 4.00; 3.25; 3.75 score on a scale

Primary: Weight Change From Baseline to Week 32 — -1.8; -6.3; -6.8 pounds — p=<0.025

Primary: Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers — 1.014; 1.062; 0.979; 1.131 Ratio…

Primary: Area Under the Curve (AUC) of ABX464 in Sera — 306.0; 63.7; 63.7; 119.8 ng*h/mL

Primary: 11-item Patient Satisfaction Questionnaire — 4.6; 4.4; 4.6; 4.3 units on a scale

Primary: Percent Bacteria Biofilm — 32.78; 20.14; 11.8; 74.03 percentage of disc covered